Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 3Carcinoma 3Pancreatic Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

reolysin 1IFL protocol 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ras-mutated Metastatic Colorectal Cancer × reolysin × Clear all
NCT07446322 2026-05-05

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Oncolytics Biotech

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Ras-mutated Metastatic Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡